美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Inotek Pharmaceuticals Corporation

3.04

0.0000

成交量：- -

成交額：- -

市值：8,211.04萬

市盈率：-1.99

高：3.04

開：3.04

低：3.04

收：3.04

52周最高：3.80

52周最低：0.8500

股本：2,701.00萬

流通股本：1,206.00萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-1.5300

淨資產收益率：--

總資產收益率：--

市淨率：1.43

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Inotek Pharmaceuticals Corporation

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.inotekpharma.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

Inotek製藥公司是於1999年7月7日根據美國特拉華州法律成立。該公司是一家臨床階段的生物製藥公司，專註於治療青光眼藥物的發現，開發和商業化。該公司領先的候選產品，trabodenoson，是一級可選擇的腺苷模擬，腺苷模擬是該公司通過恢複眼睛的自然壓力控制機制來降低眼壓機制。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ITEK/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ITEK","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ITEK\",,,,,undefined,":{"symbol":"ITEK","market":"US","secType":"STK","nameCN":"Inotek Pharmaceuticals Corporation","latestPrice":3.04,"timestamp":1515099600000,"preClose":3.04,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":12060000,"shares":27010000,"eps":-1.53,"marketStatus":"退市","change":0,"latestTime":"02-18 15:53:29 EST","open":3.04,"high":3.04,"low":3.04,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.53,"tradingStatus":0,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1771448400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":3.04,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ITEK\",,,,,undefined,":{"symbol":"ITEK","floatShares":12060000,"roa":"--","roe":"--","lyrEps":0,"shares":27010000,"dividePrice":0,"high":3.04,"amplitude":0,"preClose":3.04,"low":3.04,"week52Low":0.85,"pbRate":"1.43","week52High":3.8,"institutionHeld":0,"latestPrice":3.04,"eps":-1.53,"divideRate":0,"volume":0,"delay":0,"ttmEps":-1.53,"open":3.04},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ITEK\",params:#limit:5,,,undefined,":[{"date":"2018-01-05","symbol":"ITEK","newSymbol":"RCKT","type":"symbolChange","dateTimestamp":1515128400000},{"market":"US","date":"2017-12-27","symbol":"ITEK","name":"Inotek Pharmaceuticals Corporation","time":"","type":"earning","dateTimestamp":1514350800000,"reportTimeType":""},{"market":"US","date":"2017-08-03","symbol":"ITEK","fiscalQuarterEnding":"2017/06","expectedEps":-0.54,"name":null,"time":"","type":"earning","dateTimestamp":1501732800000,"reportTimeType":"","actualEps":-0.24},{"market":"US","date":"2017-05-10","symbol":"ITEK","fiscalQuarterEnding":"2017/03","expectedEps":-0.35,"name":null,"time":"","type":"earning","dateTimestamp":1494388800000,"reportTimeType":"","actualEps":-0.4},{"market":"US","date":"2017-03-16","symbol":"ITEK","fiscalQuarterEnding":"2016/12","expectedEps":-0.39,"name":null,"time":"","type":"earning","dateTimestamp":1489636800000,"reportTimeType":"","actualEps":-0.48}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ITEK\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ITEK\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.inotekpharma.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0134},{"period":"1month","weight":-0.0127},{"period":"3month","weight":0.0305},{"period":"6month","weight":0.0744},{"period":"1year","weight":0.12},{"period":"ytd","weight":0.0014}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Inotek製藥公司是於1999年7月7日根據美國特拉華州法律成立。該公司是一家臨床階段的生物製藥公司，專註於治療青光眼藥物的發現，開發和商業化。該公司領先的候選產品，trabodenoson，是一級可選擇的腺苷模擬，腺苷模擬是該公司通過恢複眼睛的自然壓力控制機制來降低眼壓機制。","exchange":"NASDAQ","name":"Inotek Pharmaceuticals Corporation","nameEN":"Inotek Pharmaceuticals"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"ITEK\",market:\"US\",,,undefined,":null}}